TaiRx Past Earnings Performance

Past criteria checks 0/6

TaiRx has been growing earnings at an average annual rate of 0.2%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 18.7% per year.

Key information

0.2%

Earnings growth rate

13.6%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate18.7%
Return on equity-25.8%
Net Margin-3,454.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth

Mar 24
Companies Like TaiRx (GTSM:6580) Are In A Position To Invest In Growth

We Think TaiRx (GTSM:6580) Can Afford To Drive Business Growth

Dec 09
We Think TaiRx (GTSM:6580) Can Afford To Drive Business Growth

Revenue & Expenses Breakdown

How TaiRx makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6580 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245-18444146
31 Mar 245-19844160
31 Dec 235-21244173
30 Sep 236-21145171
30 Jun 236-20946169
31 Mar 237-21047169
31 Dec 227-21249168
30 Sep 226-19347151
30 Jun 226-17446133
31 Mar 225-15047109
31 Dec 215-1264884
30 Sep 214-1194877
30 Jun 213-1134870
31 Mar 213-1364795
31 Dec 203-15946119
30 Sep 203-19847126
30 Jun 203-23749134
31 Mar 203-22747126
31 Dec 193-21846119
30 Sep 192-21245144
30 Jun 192-20543169
31 Mar 192-20741173
31 Dec 182-21039177
30 Sep 181-18338150
30 Jun 180-15636124
31 Mar 180-14336110
31 Dec 170-1303695
30 Sep 170-1213587
30 Jun 170-1113478
31 Mar 170-1153682
31 Dec 160-1193885
30 Sep 160-1183687
30 Jun 160-1173488
31 Mar 160-1053080
31 Dec 150-932672
31 Dec 140-13020112
31 Dec 131-32330

Quality Earnings: 6580 is currently unprofitable.

Growing Profit Margin: 6580 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6580 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.

Accelerating Growth: Unable to compare 6580's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6580 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.8%).


Return on Equity

High ROE: 6580 has a negative Return on Equity (-25.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 15:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TaiRx, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution